---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Administration"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Administration. Topics: Preparation, administration session of approximately six to eight hours, and post-administration follow-up; Session setting and discharge; Preparatory and follow-up sessions in the phase 2b trial; Compass Psychological Support Model and therapist training; 6 further topics. 10 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/administration"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Administration

<a id="heading-2.1.2.10.2"></a>

## 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

### Preparation, administration session of approximately six to eight hours, and post-administration follow-up

> “Our trial protocols provide that such support is delivered over three different phases: preparation, the COMP360 administration session, and post-administration follow-up.”
> “The objectives of the preparation sessions are to establish a therapeutic alliance between the patient and healthcare professional, and to demonstrate and practice the skills of self-directed inquiry and experiential processing, which we believe are critical for embracing the psychedelic experience in the psilocybin administration session.”
> “A COMP360 administration session lasts approximately six to eight hours and at least one healthcare professional is present throughout the session to monitor and safeguard participants in our clinical trials.”
> “The objectives of the follow-up sessions are to help patients process the range of emotional and physical experiences facilitated by the psychedelic experience and to integrate any new insights that can lead to cognitive and behavioral changes.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.2.10.2-2"></a>

### Session setting and discharge

> “The session takes place in a room designed to have a comfortable and calming ambience.”
> “Patients wear eye shades to help them focus internally, lie on a bed, and listen to a carefully curated music playlist through a high-quality sound system and earphones.”
> “After the acute effects of psilocybin subside, patients are evaluated for safety and discharged.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.2.10.2-3"></a>

### Preparatory and follow-up sessions in the phase 2b trial

> “Prior to administration, participants received at least one, and up to three, preparatory sessions with an assigned healthcare professional, in order to be informed and prepared for the COMP360 psilocybin session.”
> “Participants received two post-administration follow-up sessions with their healthcare professionals in which the psychedelic experience was discussed.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.2.10.2-4"></a>

### Compass Psychological Support Model and therapist training

> “The authors describe the Compass Psychological Support Model (CPSM), currently used to support participants with treatment-resistant depression in Compass-sponsored clinical trials of investigational COMP360 psilocybin treatment.”
> “The authors also outline the therapist training, mentoring, and fidelity assessment programs they have developed to ensure the quality and consistency of the CPSM delivery.”

Source: [Kirlić et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39741434/)

> “The FDA currently requires all United States therapists to have at least a Masters' level of education and that two trained therapists are present for all psilocybin sessions.”

Source: [Tai et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7908919/)

<a id="topic-2.1.2.10.2-5"></a>

### Support provided during administration sessions

> “The vast majority (78%) of the administration session was spent in silence.”
> “Support strategies include breath and body awareness, short verbal cues, and physical proximity.”

Source: [COMPASS Pathways support model publication release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Publication-of-Post-Hoc-Analysis-Demonstrating-Distinction-of-COMP360-Trial-Monitoring--Support-from-Psychotherapy/default.aspx)

<a id="topic-2.1.2.10.2-6"></a>

### Monitoring by healthcare professionals

> “Observation by two monitors for the duration of the treatment session.”
> “A health care provider with graduate-level professional training and clinical experience in psychotherapy, licensed to practice independently, serving as the lead monitor.”
> “An assistant monitor with a nursing or bachelor’s degree and at least 1 year of clinical experience in a licensed mental health care setting.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

> “our design matches what they have guided, which is to have one primary monitor and to use CCTV to assist with the total monitoring by two total healthcare providers”
> “like the six hours versus two hours requirement”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.2.10.2-7"></a>

### Simultaneous dosing of several participants

> “administered simultaneously to up to six participants, with one-to-one psychological support – each participant having an assigned, dedicated therapist available throughout the session”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-2.1.2.10.2-8"></a>

### Expected setting after approval

> “Patient self-administers oral capsule, monitored by a licensed HCP during session”
> “Dosing and monitoring to take place at a certified treatment center”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-2.1.2.10.2-9"></a>

### Fasting and water intake in the COMP360 pharmacokinetic study

> “In the single ascending dose PK component and the fasted treatment period of the FE component, the study treatment will be administered following an overnight fast (at least 10 hours fast pre-dose).”
> “Each dose will be taken with 240 mL of water at room temperature.”

Source: [ISRCTN ISRCTN17905443](https://www.isrctn.com/ISRCTN17905443)

<a id="topic-2.1.2.10.2-10"></a>

### Serotonergic antidepressant taper before dosing in the phase 2b trial

> “Participants who were on serotonergic medications were required to taper off their medicine at least two weeks prior to the baseline (Day -1) visit.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
